article thumbnail

Study finds hepatitis C cure saved Medicaid $15 billion

PhRMA

The study finds that since curative direct-acting antiviral medications for hepatitis C were approved in 2013, even after factoring in the cost of treatment, Medicaid has saved an estimated $15 billion in avoided health care costs and nearly 285,000 Medicaid enrollees are estimated to have been cured.

211
211
article thumbnail

Medicare Part D Claims Have Increased, But 340B Prescriptions Increased Faster

Pharmacy Times

in 2013 to 19.3% The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Roche looks to grow Gazyva's reach with phase 3 lupus nephritis win

Fierce Pharma

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis. |

97
article thumbnail

Health tech company Commure to acquire Augmedix in $139M deal as AI scribe competition heats up

Fierce Healthcare

Healthcare technology company Commure plans to buy Augmedix, a healthcare artificial intelligence company founded in 2013, the companies announced Friday. | On Friday, ambient AI documentation company Augmedix announced it had been bought by Commure, a large IT vendor to healthcare systems. The deal values the company at $139 million.

article thumbnail

Study points to weaknesses in FDA accelerated approval path

pharmaphorum

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

FDA 110
article thumbnail

HPV Vaccination Rates Could Improve With Increased Reimbursement

Drug Topics

of women aged 18-59 in 2013-2014. According to the CDC, HPV is the most commonly sexually transmitted infection in the US, with a prevalence of 45.2% of men and 39.9%

article thumbnail

'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study

Fierce Pharma

Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.

FDA 110